RX-5902
- Generic Name
- RX-5902
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02003092
- Locations
- 🇺🇸
Rexahn site, Arlington, Virginia, United States
🇺🇸Rexahn Site, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath